Genetics & Genomics Research & Discovery

The latest research news in genetics and genomics.

In a meta-analysis of nearly 70,000 individuals, researchers estimated that low-frequency coding variants contribute about 5 percent of multiple sclerosis risk.

The team's Pro-Code system enabled simultaneous high-dimensional protein-level phenotyping of hundreds of genes with single-cell resolution.

The project aims to identify biomarkers for predicting response and adverse events in urothelial carcinoma patients receiving immunotherapy.

The company presented Color Data as a resource for variant classification scientists and hopes it will inspire industry peers to similarly share data.

The approach could be particularly useful for harmonizing data from large multi-site efforts as proteomics experiments continue to grow in size and complexity.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Nov
27
Sponsored by
Genialis & Roche

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Dec
06
Sponsored by
Genomenon

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.